Trial Profile
Extended Follow-up of Patients With Macular Edema Due to bRanch rETinal Vein Occlusion (BRVO) or centrAl Retinal veIn occlusioN (CRVO) Previously Treated With Intravitreal Ranibizumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Oct 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal vein occlusion
- Focus Adverse reactions
- Acronyms RETAIN
- 13 Oct 2015 New trial record